Search results
Added:
1 year ago
TCT Conference 2024 - Significant reduction in TLF and TVF and flattening of event curves after 6 months in favour of DynamX Bioadaptor.Dr David Erlinge (Skane University Hospital, Lund, SE) joins us onsite at TCT Conference to discuss the findings from INFINITY-SWEDEHEART (NCT04562805).INFINITY-SWEDEHEART is a prospective, multicenter, randomized registry-based clinical trial, where patients…
View more
Added:
5 days ago
In this episode of Arrhythmia Academy's Journal Club, Dr David Duncker (Hannover Heart Rhythm Center, DE) is joined by Dr Marat Fudim (Duke University, US) to examine the critical early-risk period following heart failure diagnosis and the emerging role of wearable cardioverter defibrillators in sudden cardiac death prevention.The discussion centres on findings from the SCD-PROTECT study, a 19…
View more
Added:
3 months ago
AHA Scientific Sessions 2025 - Phase 1 results show the CRISPR-Cas9 gene editing therapy is a safe treatment option targeting ANGPTL3 in patients with lipid disorders.Prof Stephen Nicholls (Monash Victorian Heart Institute, Clayton, AU) joins us to share results from a first-in-human phase 1 trial investigating a one-time infusion of CTX310, a CRISPR-Cas9 gene editing therapy, at different doses…
View more
Management of Calcified Coronary Lesions
Added:
2 years ago
Review Article
Added:
1 year ago
ECO 2024 — Dr Riccardo Panella (Aalborg University, DK) joins us to discuss a ncRNA-based approach in treating obesity. This new combinatory treatment (Resalis) aims to increase GLP1-RA efficacy by targeting non-coding RNA.Questions1. What is the background of this combinatory approach?2. What data did you present at ERA 24?3. What are the challenges and opportunities in approaching combinatory…
View more
Added:
2 years ago
AHA 2023 — Investigator, Dr Steven E Nissen (Cleveland Clinic, US) is interviewed by CardioNerds Medical Education Fellow, Dr Maryam Barkhordarian (HMH Palisades Medical Center, US) on the trial that assessed the efficacy and safety of lepodisiran, a small interfering RNA (NCT05565742).The main purpose of this phase 2, randomised, double-blind, placebo-controlled study (Eli Lilly and Company) is…
View more
Important Gaps in Heart Failure Care
Added:
2 months ago
Review Article
Added:
3 months ago
AHA Scientific Sessions 2025 - Dr Clyde Yancy (Northwestern University, US) joins us to explore the future trajectory of heart failure management, examining how prevention strategies, precision medicine approaches, and the evolving responsibilities of cardiologists are reshaping patient outcomes.Interview Questions:Looking at the current state of heart failure management, what do you see as the…
View more
Added:
5 months ago
ESC Congress 2025 - In this video, Dr Michelle Kittleson (Cedars-Sinai Heart Institute, US) outlines the hot-line data from the congress that are expected to have an impact on clinical practice in the heart failure space.Trials covered in detail include:REBOOT-CNIC: Beta-Blockers after Myocardial Infarction without Reduced Ejection FractionBETAMI-DANBLOCK: Beta-Blockers after Myocardial…
View more
Added:
5 months ago
ESC Congress 2025 - Vericiguat did not reduce the risk of cardiovascular mortality and hospitalization in heart failure with reduced ejection fraction, fewer cardiovascular deaths and all-cause deaths were observed.Host, Dr Harriette Van Spall (McMaster University, CA) is joined on-site at ESC Congress 2025 in Madrid by Dr Faiez Zannad (University of Lorraine, FR) to discuss pivotal results from…
View more